Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 1, 2018, Pages 157-161

  Wang, Feng ^a,b   Yin, Qian ^b   Chen, Liang ^b   Davis, Mark M ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bifidobacterium; CTLA 4; Immune checkpoint blockade; Intestinal immunopathology; Probiotics

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CTLA 4; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; CTLA4 PROTEIN, MOUSE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B16-BL6 CELL LINE; BIFIDOBACTERIUM; C57BL 6 MOUSE; CONTROLLED STUDY; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; ENTEROPATHY; FEMALE; FOXP3 DTR MOUSE; GRAM POSITIVE BACTERIUM; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INTESTINE FLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR VOLUME; ULCER; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; BIFIDOBACTERIUM; COLITIS; CTLA-4 ANTIGEN; MICE; MICE, TRANSGENIC; VANCOMYCIN;

EID: 85040181367     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1712901115     Document Type: Article

References (27)

1. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723.
2. Larkin J, et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34.
3. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571.
4. Michot JM, et al. (2016) Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 54:139–148.
5. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2:1346–1353.
6. Sivan A, et al. (2015) Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–1089.
7. Vétizou M, et al. (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079–1084.
8. Lipson EJ, Drake CG (2011) Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17:6958–6962.
9. Vrieze A, et al. (2014) Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 60:824–831.
10. Cotter PD, Stanton C, Ross RP, Hill C (2012) The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing. Discov Med 13:193–199.
11. Ghouri YA, et al. (2014) Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7:473–487.
12. Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7:503–514.
13. Pronio A, et al. (2008) Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14:662–668.
14. Ventura M, et al. (2009) Genome-scale analyses of health-promoting bacteria: Pro-biogenomics. Nat Rev Microbiol 7:61–71.
15. Jia W, Li H, Zhao L, Nicholson JK (2008) Gut microbiota: A potential new territory for drug targeting. Nat Rev Drug Discov 7:123–129.
16. Shen J, Zuo ZX, Mao AP (2014) Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20:21–35.
17. Fukuda S, et al. (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547.
18. Smith PM, et al. (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569–573.
19. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10dependent TGF-beta-bearing regulatory cells. J Immunol 174:3237–3246.
20. Calcinaro F, et al. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48:1565–1575.
21. Furusawa Y, et al. (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450.
22. Park J, et al. (2015) Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 8:80–93.
23. Michalek RD, et al. (2011) Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186:3299–3303.
24. Zeng H, Chi H (2015) Metabolic control of regulatory T cell development and function. Trends Immunol 36:3–12.
25. Galgani M, De Rosa V, La Cava A, Matarese G (2016) Role of metabolism in the im-munobiology of regulatory T cells. J Immunol 197:2567–2575.
26. Dwivedi M, Kumar P, Laddha NC, Kemp EH (2016) Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev 15: 379–392.
27. Yang Y, et al. (2014) Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510:152–156.